Evidence map›Paper›PMID 33389528›Full record

ArticleMolecular biology reports2021

Programmed cell death 1 (PDCD1) gene haplotypes and susceptibility of patients to basal cell carcinoma.

Farshid Fathi, Batool Zamani, Ahmad Piroozmand, Samaneh Mozafarpoor, Effat Seyedhashemi, Reza ArefNezhad, Hossein Motedayyen

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. The Immunogenetics of Non-melanoma Skin Cancer.Advances in experimental medicine and biology · 2022
    Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Farshid FathiDepartment of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Batool ZamaniAutoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Ahmad PiroozmandAutoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Samaneh MozafarpoorDepartment of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran.
Effat SeyedhashemiDepartment of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Reza ArefNezhadDepartment of Anatomy, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Hossein MotedayyenAutoimmune Diseases Research Center, Shahid Beheshti Hospital, Kashan University of Medical Sciences, 5th kilometer of Ravand Road, Kashan, Iran. hmotedayyen@gmail.com.
Kashan University of Medical Sciences · IRIsfahan University of Medical Sciences · IRIslamic Azad University Medical Branch of Tehran · IRShiraz University of Medical Sciences · IR

Funding

Kashan University of Medical Sciences 98019
6 · The paper itself

Abstract

Programmed death-1 (PD-1), as an immunoinhibitory receptor encoded by programmed cell death-1 (PDCD1) gene, has a pivotal role in tolerance to self-antigens. Mutations of PDCD1 may participate in susceptibility to basal cell carcinoma (BCC) as the most common of skin cancer. We studied the impacts of two single nucleotide polymorphisms (SNPs) within PDCD1 and their haplotypes in BCC susceptibility in an Iranian population. The blood samples were collected from 210 BCC and 220 healthy individuals. After the extraction of genomic DNA, the genotypes and alleles of PD1.1 G/A (rs36084323) and PD1.6 G/A (rs10204525) SNPs were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Four haplotypes were estimated by these SNPs. Our data revealed that genotype and allele frequencies of PD1.1 and PD1.6 polymorphisms in BCC patients were similar to those in healthy individuals. The results of estimated haplotypes for PDCD1 indicated that GG and AA haplotypes of PDCD1 had protective effects on BCC susceptibility (OR = 0.7, 95% CI = 0.51-0.96, p = 0.03 and OR = 0.57, 95% CI = 0.35-0.91, p = 0.02, respectively), while GA and AG haplotypes served as the risk factors for developing BCC (OR = 1.76, 95% CI = 1.09-2.84, p = 0.02 and OR = 3.87, 95% CI = 1.95-7.69, p = <0.001, respectively). Based on these findings, frequency distributions of PDCD1 haplotypes have important roles in the determination of BCC development in the Iranian population. However, larger multicenter studies are required to confirm this conclusion.

Indexed as

Genetic Predisposition to DiseaseAdolescentAdultAgedAged, 80 and overBasal Cell CarcinomaCase-Control StudiesFemaleGene FrequencyHaplotypesHumansMaleMiddle AgedPolymorphism, Single NucleotideProgrammed Cell Death 1 ReceptorSkin NeoplasmsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorBasal cell carcinomaHaplotypePolymorphismProgrammed cell death-1

Identifiers

PMID33389528
OpenAlexW3121026872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.